NCT01835730View on ClinicalTrials.gov

Phase 1 Multicenter, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of PE0139 Injection in Adult Subjects With Type 2 Diabetes Mellitus

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
DRUG

PE0139 Injection

DRUG

Placebo

Trial Locations (3)

33012

Palm Springs Research Institute, Hialeah

36207

Pinnacle Research Group, LLC, Anniston

98057

Rainier Clinical Research, Renton

Sponsors
All Listed Sponsors
lead

PhaseBio Pharmaceuticals Inc.

INDUSTRY